Table 2.
Laboratory abnormalities in 3 patients treated for TMA following IV abuse of extended-release oxymorphone
| Patient 1 | Patient 2 | Patient 3 | ||||
|---|---|---|---|---|---|---|
| Test result | Presentation | Peak or nadir | Presentation | Peak or nadir | Presentation | Peak or nadir |
| WBC, 4.5-11 × 109/L | 12.6 | 12.8 | 23.3 | 30.2 | WNL | WNL |
| Hemoglobin, 13.5-17.5 g/dL | 11.2 | 9.9 | 7.7 | 4.7 | 7.7 | 6.9 |
| Hematocrit, 35%-50% | 31.9 | 27.8 | 22.8 | 14.3 | 23.3 | 20.4 |
| Platelet count, 150-450 × 109/L | 43 | 41 | 18 | 13 | 20 | 20 |
| Creatinine, 0.6-1.3 mg/dL | WNL | WNL | 2.2 | 5.3 | 1.6 | 1.7 |
| LDH, 140-280 U/L | 1507 | 1507 | 1981 | 4418 | 2584 | 2854 |
| Haptoglobin, 30-200 mg/dL | Undetectable | Undetectable | Undetectable | |||
| ADAMTS13 | 66% | 64% | ND | |||
| D-dimer, ≤0.5 µg/mL | 0.97 | 0.97 | ND | ND | ||
| C3, 88-252 mg/dL | 45 | 44 | WNL | 22 | 73 | 69 |
| C4, 12-75 mg/dL | 6 | 6 | WNL | 5 | 10 | 6 |
| CH-50, 31-60 U/mL | 24 | 24 | WNL | 13 | WNL | WNL |
| Troponin I, <0.01 ng/mL | 6.14 | 6.14 | 4.95 | 27.2 | 12.83 | 22.53 |
| Hepatitis B antibody | Negative | Negative | Negative | |||
| Hepatitis C antibody | 13.73 | Negative | Negative | |||
| Echocardiography | EF 55% | EF 30%, mild RV and LV dilation | EF 20%, global hypokinesis, moderate RA dilation | |||
EF, left ventricular ejection fraction; LV, left ventricular; ND, not determined; RA, right atrial; RV, right ventricular; WNL, result within reference range.